Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Imatinib-Resistant/Intolerant CML and Ph+ ALL
NCT00337454Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2005
- Primary completion
- Mar 2007
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of dasatinib in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) (6 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety of BMS-354825 at 4 weeks, Cytogenetic Response and 1 more. Started Jul 2005; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00337454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00337454.